Abstract
Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have